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Abstract
Objectives: Olanzapine, an atypical antipsychotic drug with affinities for dopamine, serotonin, 
and histamine binding sites appears to be associated with substantial weight gain and metabolic 
alterations. The aim of this study was to evaluate weight gain and metabolic alterations in rats 
treated with olanzapine on a hypercaloric diet. Methods: We used 40 rats divided into 4 groups: 
Group 1, standard food and water conditions (control); Group 2, standard diet plus olanzapine; 
Group 3, cafeteria diet (hypercaloric); and Group 4, olanzapine plus cafeteria diet. Olanzapine 
was administered by gavage at a dose of 3 mg/kg for 9 weeks. Results: There were no significant 
changes in the cholesterol levels in any group. Glucose levels increased in Group 3 by the fourth 
week. Triglyceride levels were altered in group 2 toward the end of the experiment. Leptin levels 
decreased in Groups 2 and 4. Complex II activity in the muscles and liver was altered in Group 
2 (muscle), and Groups 2, 3, and 4 (liver). Complex IV activity was altered only in the liver in 
Group 2, without significant alterations within the muscles. Conclusion: These results suggest 
that olanzapine is correlated with weight gain and the risks associated with obesity.
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Metabolismo calórico, leptina e parâmetros bioquímicos se alteram em ratos 
submetidos à administração crônica de olanzapina
Resumo
Objetivos: A olanzapina, uma droga antipsicótica atípica com afinidade por locais de ligação 
de dopamina, serotonina e histamina, parece se associar a um ganho de peso e a alterações 
metabólicas consideráveis. O objetivo desse estudo foi avaliar o ganho de peso e as alterações 
metabólicas em ratos tratados com olanzapina numa dieta hipercalórica. Métodos: Usamos 40 
ratos divididos em 4 grupos: Grupo 1, condições padrão de alimento e água (controle); Grupo 2, 
dieta padrão mais olanzapina; Grupo 3, dieta  hipercalórica; e Grupo 4, olanzapina mais dieta 
hipercalórica. Olanzapina foi administrada por gavagem a uma dose de 3 mg/kg por 9 semanas. 
Resultados: Não houve alterações significativas nos níveis de colesterol em qualquer um dos 
grupos. Os níveis de glicose aumentaram no Grupo 3 por volta da quarta semana. Os níveis 
de triglicerídeos estavam alterados no Grupo 2 ao final do experimento. Os níveis de leptina 
diminuíram nos Grupos 2 e 4. A atividade do complexo II nos músculos e no fígado se alterou no 
Grupo 2 (músculos) e nos Grupos 2, 3 e 4 (fígado). A atividade do complexo IV se alterou apenas 
no fígado no Grupo 2, sem alterações significativas nos músculos. Conclusão: Esses resultados 
sugerem que olanzapina se correlaciona ao ganho de peso e aos riscos associados à obesidade.
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Introduction
Schizophrenia is one of the most intriguing and widely 
studied mental diseases. Cognitive impairment related to 
schizophrenia produces neuropsychological deficits in vari-
ous functions, including attention, working memory, verbal 
learning, and problem-solving/executive functions. Such 
deficits are directly related to functional changes in social 
behavior, occupational performance, and daily activities.1 
According to Harrison,2 schizophrenia patients’ brains show 
abnormalities, including ventricular enlargement and de-
creased cerebral (cortical and hippocampal) volume (which 
triggers the initial symptoms), as well as an absence of gliosis 
and other neurodegenerative features.
The symptoms of this highly debilitating psychiatric disor-
der are traditionally divided into 3 primary clusters: positive 
(hallucinations, delusions, and catatonia), negative (social 
and affective withdrawal) and disorganized (bizarre behavior, 
thought disorganization, and impropriated affection). Due 
to the symptoms frequency and severity, schizophrenia is a 
heterogeneous disease that is difficult to treat.3
Atypical antipsychotic drugs are prescribed as a first-line 
intervention and represent a great advance in schizophrenia 
drug treatment.4 According to Reinke et al.,5 atypical anti-
psychotic drugs such as olanzapine seem to confer a lower 
risk of extra-pyramidal side effects compared to typical 
antipsychotics, and provide good antipsychotic properties. 
Olanzapine is an atypical thienobenzodiazepine-class anti-
psychotic with an affinity for dopamine binding sites D1 and 
D4, as well as serotonin 5-HT,
2,3,6 muscarin (subtypes 1–5), 
adrenergic (alfa1), and histamine (H1) binding sites. The 
drug possesses weak D2 receptor blockade properties, and 
its serotonin receptor 5-HT2A blockage is about 8 times more 
intense than that of dopamine receptor D2.
6 Clinical assay 
suggests that olanzapine decreases both positive and negative 
symptoms, and that it is associated with a low incidence of 
extra-pyramidal side effects.7
Despite the advantages of atypical antipsychotics over 
typical ones, their use, especially olanzapine, is related to 
significant weight gain and metabolic alterations such as dyslip-
idemias, diabetes, and other problems involving the metabolic 
syndrome.7 These metabolic alterations significantly increase 
the risk of death from cardiovascular disease, which is already 
the major cause of mortality in patients with schizophrenia.8 
Furthermore, according to Jacob et al.,7 even without treat-
ment, patients with schizophrenia have a higher risk for obesity, 
type 2 diabetes mellitus (DM), hypertension, and dyslipidemia 
compared to the general population. Weight gain is a common 
and severe side effect of atypical antipsychotic drugs; there-
fore, animal models are used to elucidate the mechanisms that 
lead to such alterations.9 Although most cases of antipsychotic-
induced hyperglycemia and type 2 DM are associated with 
substantial weight gain, a significant number of cases occur 
among non-obese patients. Some studies indicate that first-
episode drug-naive patients with schizophrenia have 3 times 
the visceral adiposity, a lower glucose tolerance and stronger 
insulin resistance when compared to matched control groups.10,11 
Atypical antipsychotic drug-induced weight gain has 
multiple causes. Many of these drugs stimulate the appetite, 
generating a preference for sweet or greasy foods, which 
suggests a direct action on the metabolic systems and the 
centers of the brain associated with satiety and weight con-
trol.11 Bear et al.11 reported the important role of the dopa-
minergic system in regulating motivation, including feeding 
behavior. Thus, when dopaminergic neurons are destroyed 
or their receptors are blocked by drugs, electrical stimula-
tion is much less effective in triggering feeding behavior. 
Antipsychotic-induced weight gain occurs even in the pres-
ence of high levels of leptin. Therefore, it is postulated that 
such drugs can reduce the sensitivity of the hypothalamus 
to the action of leptin.12 
Molecular mechanisms for leptin and insulin signaling in 
the hypothalamus are responsible for neural appetite regula-
tion.13 Leptin is an adipocyte-secreted, negative-feedback 
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hormone that acts on the hypothalamus to regulate both 
food intake and energy expenditure.13 There are at least two 
distinct neuronal groups that both possess leptin receptors 
in the arcuate nucleus: orexigenic neurons, which produce 
neuropeptide Y (NPY) and agouti-related protein (AGRP) and 
anorexigenic neurons, which produce proopiomelanocortin 
(POMC) and cocaine- and amphetamine-regulated transcript 
(CART). Thus, leptin acts in catabolic and anabolic pathways 
via POMC and NPY, respectively.14 Data shows that antipsy-
chotic-induced weight gain may be related to a dysfunction 
in leptin levels.15 In addition, abnormalities in glucose me-
tabolism are described among atypical antipsychotic-treated 
patients with schizophrenia.16
Strategies to prevent alterations to the metabolic system 
are important in understanding the mechanisms underlying 
lipid metabolism, their association with changes in energy 
metabolism, and the control of reactive oxygen species 
formation.17 In vitro experiments have been developed to 
study how the use of atypical antipsychotic drugs affects 
lipid metabolism in adipocytes;18 a study suggests that these 
mechanisms can be modulated through mitochondrial activ-
ity,19 mainly by the inhibition of complex I.20
In addition, the use of atypical antipsychotics not only 
alters the metabolism responsible for the homeostasis of the 
metabolic system, but also alters the energetic metabolism 
of the brain.21,22 Ji et al.22 demonstrated that olanzapine 
acts by inhibiting the enzymatic activity of complex I of the 
mitochondrial respiratory chain in some brain areas, such as 
the cerebral cortex and hippocampus, in addition to inhibit-
ing subunits of complex V or adenosine triphosphate (ATP) 
synthase.22 Since antipsychotics act directly on the dopamine 
and serotonin pathways, the interaction leads to dopamine’s 
modulation of the electron transport chain functioning by 
diminishing complex I activity, ATP synthesis, and membrane 
potential.23,24
Considering schizophrenia is a complex and incurable 
disease and that drugs currently used for its management 
have potential side effects that make the maintenance 
of treatment difficult, the aim of our study is to evaluate 
metabolic alterations as well as the weight gain in animals 
treated with olanzapine and cafeteria diets.
Methods
Male 60-day-old Wistar rats were obtained from the 
Central Animal House of the Universidade do Extremo Sul 
Catarinense. They were caged in groups of 5, given free 
access to food and water and maintained in a 12-h light/
dark cycle (lights on 7:00 am) at 22 (1)°C. All experimental 
procedures were carried out in accordance with the National 
Institute of Health’s ‘Guide for the Care and Use of Laboratory 
Animals’ and the Brazilian Society for Neuroscience and 
Behavior’s (SBNeC) Recommendations for Animal Care with 
the approval of the Ethics Committee of the Universidade 
do Extremo Sul Catarinense.
Animals were randomly divided into 4 groups: Group 1 
(sham animals) received a standard diet plus saline adminis-
tration, Group 2 received the standard diet plus olanzapine 
administration, Group 3 received a cafeteria (hypercaloric) 
diet plus saline administration, and Group 4 received the 
cafeteria diet plus olanzapine administration.
Olanzapine treatment consisted of one gavage administra-
tion (3 mg/kg olanzapine) per day for 9 weeks. Sham animals 
and group 3 received saline by gavage. The animals were 
weighed weekly during the 9 weeks of treatment.
The hypercaloric diet - designated cafeteria (Table 1) – 
consisted of food that was changed daily, All food was pro-
cessed, mashed, and mixed with standard food for rats (1:1, 
cafeteria diet food: normal ration).
Determination of glucose, cholesterol, and triglycerides: 
these parameters were determined by Laboratório Búrigo. 
Blood was collected at the beginning of treatment, on the 
fourth week, and at the end of the treatment period.
Determination of leptin blood levels: leptin blood levels 
were determined using an ELISA Millipore Rat Leptin® com-
mercial kit. The measurements were performed using blood 
collected at the end of the treatment period.
At the end of the treatment period, the animals were 
sacrificed by decapitation without anesthesia; the liver and 
muscles were removed to evaluate the activity of respiratory 
chain complexes II and IV. The livers and skeletal muscles 
were homogenized (1:20, w/v) in SETH buffer (pH 7.4; 
250 mM sucrose, 2.0 mM EDTA, 10 mM Trizma base, and 
50 UI/mL heparin). The homogenates were centrifuged at 
800 × g for 10 min, and the supernatants were kept at -70°C 
until they were used for enzyme activity determination. The 
period between tissue preparation and enzyme analysis was 
always less than 5 days.
The activities of succinate-2,6-dichloroindophenol (DCIP)–
oxidoreductase (complex II) and succinate:cytochrome c oxi-
doreductase (complex II–III) were determined in homogenates 
of the cerebral cortex as described previously.25 The activity 
of cytochrome c oxidase (complex IV) was assayed in cerebral 
cortex homogenates.25 The activities of the respiratory chain 
complexes were calculated as nmol·min-1·mg-1 protein.
Protein was measured using the method described by 
Lowry et al.26 using bovine serum albumin as standard.
Statistical analysis
We performed Shapiro-Wilk and Levene median tests to as-
sess normality and equal variance, respectively. If p > 0.05 
was reached for both tests, we compared means using 
repeated measures ANOVA or one/two way analysis of vari-
ance (ANOVA) (both identified by F values). Otherwise, the 
non-parametric equivalent tests were performed (Friedman 
Repeated Measures ANOVA on Ranks or Kruskal Wallis ANOVA; 
both identified by H values). Friedman Repeated Measures 
ANOVA on Ranks was followed by Dunnett’s test.
Results
Weight
All groups have gained weight throughout the nine week 
period (control group χ2 = 70.47, p < 0.001; olanzapine 
χ2 = 70.94, p < 0.001; hypercaloric diet χ2 = 68.90, p < 0.001; 
olanzapine + hypercaloric diet χ2 = 68.90, p < 0.001). The 
group treated with olanzapine + hypercaloric diet showed a 
significant weight difference starting from the fourth week 
while it took five weeks for all other groups (Table 2). Weight 
change throughout the nine weeks showed normal distribu-
tion but no significant difference between the four groups 
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Table 1 Hypercaloric diet (cafeteria diet). This diet was used in the hypercaloric diet and hypercaloric diet plus 
olanzapine groups for 10 weeks
Diet Components of Diet Weight Days
1
Chocolate cookie
Chantilly
Corn salted
Peanut sweet
5 g of each component every day 3 consecutive days
2
ChocoIate
Chocolate cookie
Peanut
5 g of each component every day 3 consecutive days
3
Bacon salted
Chantilly
Corn salted
5 g of each component every day 3 consecutive days
4
Thread of Milk
Peanut
Peanut
5 g of each component every day 3 consecutive days
5
Chocolate cookie
Bacon salted
Thread of Milk
5 g of each component every day 3 consecutive days
6
Bacon salted
Peanut
Supplied cookies
5 g of each component every day 3 consecutive days
7
French fries
Peanut
ChocoIate
5 g of each component every day 3 consecutive days
8
Cheese
Peanut Sweet
Supplied cookies
5 g of each component every day 3 consecutive days
9
Peanut sweet
Cheese
Cheese
5 g of each component every day 3 consecutive days
10
Thread of Mil
Supplied cookies
5 g of each component every day 3 consecutive days
It was added 15 g of normal ration to complement the diet.
Table 2 Weight gain evaluations of the group undergoing chronic administration of olanzapine while receiving the 
hypercaloric diet for 9 weeks. Data is expressed as median (25, 75 percentiles).
Group Control Olanzapine Hypercaloric diet Olanzapine + Hypercaloric diet
P1 277 (250, 290) 260.5 (257, 274) 272 (259.5, 296.5) 273 (252.5, 280.5)
P2 297.5 (269, 309.5) 281 (271.5, 296.5) 283 (271, 302) 285 (260.5, 292)
P3 316 (287, 330) 307.5 (296, 314.5) 312 (299.5, 345) 306 (280.5, 317)
P4 325 (297.5, 344) 325.5 (309, 331.5) 335 (318, 356.5) 327.5 (301, 340)
P5 346.5 (322, 357) 332.5 (324, 339) 350 (343.5, 381) 341.5 (311, 357.5)*
P6 354.5 (331.5, 369)* 344 (331.5, 354)* 363 (349.5, 394.5)* 352.5 (320, 369.5)*
P7 357 (343, 377)* 354 (351, 366.5)* 367 (348.5, 407)* 350 (314.5, 371)*
P8 366.5 (341.5, 388.5)* 365 (357.5, 377.5)* 390.5 (371, 414)* 367.5 (330.5, 384.5)*
P9 372 (354.5, 384.5)* 374 (362, 380)* 402.5 (386, 428.5)* 387.5 (344, 398.5)*
P10 383 (362.5, 398)* 379.5 (360.5, 386.5)* 414 (388.5, 431)* 391 (347, 404)*
Data is present as median (0.25, 0.75 percentile). *p < 0.05 compared to P1.
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was observed (F = 1.69, p = 0.189). Furthermore, we did 
not observe an interaction between a hypercaloric diet and 
olanzapine treatment (F = 1.75, p = 0.196).
Serum analysis
Serum cholesterol was measured at the baseline on the 
fourth and ninth week. We observed a statistical trend for 
an increased cholesterol level in the olanzapine and olan-
zapine + hypercaloric diet groups (control group χ2 = 5.33, 
p = 0.072; olanzapine χ2 = 6.33, p = 0.052; hypercaloric diet 
χ2 = 3.50, p = 0.273; olanzapine + hypercaloric diet χ2 = 6.00, 
p = 0.500). There was no significant difference in the cho-
lesterol changes between groups (fourth week H = 1.35, 
p = 0.716; ninth week F = 1.01, p = 0.405). Moreover, we did 
not observe an interaction between the hypercaloric diet 
and olanzapine treatment (fourth week F = 0.01, p = 0.998; 
ninth week F = 2.45, p = 0.130).
Glucose serum levels were measured on the baseline on the 
fourth and ninth week. We observed lower glucose levels 
after both olanzapine treatment and/or a hypercaloric diet 
in all groups (control group χ2 = 12.07, p = 0.0003; olanzapine 
χ2 = 11.14, p = 0.001; hypercaloric diet χ2 = 12.28, p = 0.0003; 
olanzapine + hypercaloric diet χ2 = 10.33, p = 0.002). We 
found a lower glucose change in the hypercaloric diet group 
when compared to the control group after four weeks 
(F = 3.31, p = 0.03, post hoc p = 0.005). Results showed 
no interaction between treatments (fourth week F = 2.19, 
p = 0.151; ninth week F = 0.02, p = 0.871).
Serum triglyceride levels were measured on the fourth and 
ninth week. We observed increased triglycerides in the olan-
zapine group after treatment for nine weeks (control group 
χ2 = 3.50, p = 0.273; olanzapine χ2 = 7.00, p = 0.029; hyper-
caloric diet χ2 = 3.71, p = 0.192; olanzapine + hypercaloric 
diet χ2 = 2.00, p = 0.486) (Table 3). There was a significant 
triglyceride change after nine weeks of clozapine treatment 
when compared to control (fourth week H = 3.58, p = 0.310; 
9th week F = 5.35, p = 0.005, control x olanzapine p = 0.004). 
We have also found statistically significant results for the 
interaction between hypercaloric diet and olanzapine treat-
ment after nine weeks (fourth week F = 0.174, p = 0.681; 
ninth week F = 9.47, p = 0.005).
Leptin serum level was measured after nine weeks of 
treatment. Our results indicate that the olanzapine + hyper-
caloric diet group showed statistically significant lower leptin 
levels than the control group after nine weeks of treatment 
(H = 17.36, p = 0.0005, post hoc olanzapine + hypercaloric 
diet x control p = 0.001)
Respiratory chain complex II and IV, present in the skeletal 
muscles and livers of rats subjected to olanzapine adminis-
tration in the absence or presence of the hypercaloric diet, 
were also measured. 
We observed an increase in muscle complex II activity in 
the olanzapine-administered group (F = 4.45 p = 0.02, con-
trol x olanzapine p = 0.02). Similarly, the hepatic complex 
II activity increased (F = 11.23, p < 0.01) in the olanzapine 
(p = 0.011), cafeteria diet (p = 0.001), and olanzapine plus 
cafeteria diet (p = 0.001) groups (Figure 1). Furthermore, 
hepatic complex IV activity increased in the olanzapine 
group (F = 9.83, p = 0.001, control x olanzapine p = 0.002) 
(Figure 2).
Discussion
Cholesterol levels
In the present study, we did not observe significant alterations 
in blood cholesterol levels after treatment with olanzapine or 
the hypercaloric diet. Teixeira et al.27 report that most of the 
studies concerning dyslipidemia and psychopharmaceuticals 
highlight antipsychotic drugs, particularly clozapine and olan-
zapine, as presenting an increased risk of general cholesterol 
increase. Koro et al.28 analyzed a database containing over 
18,000 patients with schizophrenia and concluded that olan-
zapine treatment is related to a nearly 5-fold increase in the 
incidence of dyslipidemia compared to the general population 
and an over 3-fold increase in typical antipsychotic-treated 
Table 3 Cholesterol, glucose and triglyceride evaluation in the baseline, at the 4th and 9th week of the experiment. 
Leptin was evaluated only at the end of the experiment.  Data is expressed as median (25, 75 percentiles).
Group Control Olanzapine Hypercaloric diet Olanzapine + Hypercaloric diet
Chol. Baseline 52.5 (45.5, 58.5) 54.5 (51.5, 62) 54 (47.75, 59.25) 55.5 (50.5, 58)
4th week 65 (62, 75) 72 (64, 80) 74.5 (69, 86) 85.5 (67.25, 87.75)
9th week 62 (54, 71) 73 (66.5, 75.5) 69 (61.25, 75.5) 57 (55.5, 70.5)
Gluc. Baseline 226 (207.5, 315) 255 (221, 295.75) 210 (197.25, 233.5) 221 (202, 257)
4 th week 157 (124.25, 163.5)* 164 (147, 169.75)* 187 (173.75, 201.75) 165 (161, 169)
9 th week 136.5 (126.5, 143.5)* 136 (113, 137.75)* 134 (129, 147.5)* 141.5 (128, 146)*
Triglyc. Baseline 92(75, 114) 98 (68.5, 118) 107 (63, 113.75) 107.5 (87, 129)
4th week 161 (139, 180) 111.5 (109, 129) 112 (90, 245.5) 119 (91, 143.75)
9th week 136.5 (132, 154) 316 (224, 403)* 182 (109, 249.5) 133 (118, 167.5)
Leptin 9th week 0.372 (0.278, 0.436) 0.243 (0.164, 0.294) 0.414 (0.326, 0.506) 0.224 (0.114, 0.267)
Chol: Cholesterol; Gluc: Glucose; Triglyc: Triglycerides.
Data is present as median (0.25, 0.75 percentile). *p < 0.05 compared to baseline.
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patients. Although data from the literature remain contro-
versial, in the present study, 3 mg/kg doses of olanzapine 
did not significantly affect cholesterol levels; this can be 
explained due to the short duration of treatment consider-
ing that the references cited above utilized longer periods 
of treatment. Nevertheless, another study corroborates our 
findings, indicating either small or non-significant increases 
in lipid levels as a result of olanzapine administration.29
Triglyceride levels
Triglyceride levels increased in Group 2 (treated with 
olanzapine only) at the end of treatment. Previous studies 
indicate a more significant increase in triglyceride levels 
compared to cholesterol levels.29,30 The first published study 
comparing treatment with atypical (e.g., olanzapine) and 
typical (e.g., haloperidol) antipsychotics indicates a signifi-
cant increase in triglyceride levels among patients treated 
with olanzapine.31  
Glucose levels
We found increased glucose levels in Group 3 (cafeteria diet 
without olanzapine) during the fourth week (the middle 
of treatment). We suggest that this alteration, which was 
verified only at the fourth week and disappeared following 
treatment,32 is an adaptation to the hypercaloric diet. An 
experimental study with rats conducted by Coccurello et al.32 
found increased glucose levels, even in the presence of high 
insulin levels, when olanzapine was administered at 3 mg/kg. 
This suggests that the outcome is attributable to insulin 
resistance.32 Sena et al.30 reported that glucose metabolic 
alterations are more common in patients with schizophrenia 
than in the general population. They concluded that hy-
perglycemia is not dose-dependent in most cases, that it is 
reversible with treatment cessation and reappears once the 
antipsychotic is re-administered. In addition, some reports 
suggest that atypical antipsychotic drugs like olanzapine have 
a strong affinity for serotoninergic receptors (i.e., 5HT1A and 
5HT2), resulting in the reduction of pancreatic cell activity.
33 
Leptin levels
Decreased levels of blood leptin were found in Groups 2 and 
4 (treatment with olanzapine plus cafeteria diet and olanzap-
ine alone, respectively). Findings related to the association 
of leptin action and the use of atypical antipsychotic drugs 
remain limited and controversial. Treatment with atypical 
antipsychotics increase body weight by 20%, and leptin 
appears to be responsible for such results.24 Another study 
indicates that leptin receptor levels are not altered, suggest-
ing leptin resistance to its own receptors in patients treated 
with olanzapine34 or a leptin blockade caused by olanzapine 
that results in weight gains.35 
Figure 1 Effects of olanzapine and hypercaloric diet administration on the activity of complex II of the respiratory chain in 
rat liver and muscles. Data is expressed as mean ± SD (n = 10). 
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Figure 2 Effects of olanzapine and hypercaloric diet administration on complex IV of the respiratory chain in rat liver and 
muscles. Data is expressed as mean ± SD (n = 10).
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The olanzapine-induced blockade of neurotransmitters in 
the hypothalamus has been studied in rats. Since it appears 
that this drug is involved in the blockade of receptors 5HT2C, 
D2 and H1, satiety signaling does not occur, which consequently 
increases food intake and body weight36 Danaci et al.37 observed 
weight gain within an olanzapine-treated group, although low 
leptin levels were maintained at the end of the experiment. 
Studies suggest that low leptin levels slow down satiety signal-
ing to the hypothalamus, resulting in increased appetite and 
subsequent weight gain.37 Our findings are corroborated by the 
data from these studies, indicating that leptin levels are lower 
than normal, thus, inducing weight gain via the inhibition of 
the satiety sensation. This can result in obesity and subsequent 
health problems from continuous use of the medication. 
Mitochondrial respiratory chain
A previous study on patients with schizophrenia found mem-
brane alterations and mitochondrial dysfunction.38 We evalu-
ated the activity of complexes II and IV of the mitochondrial 
respiratory chain within the muscles and liver. In muscle tissue, 
we observed a significant increase in complex II activity within 
the olanzapine-treated group compared to the saline group. 
In the liver, we found increased complex II activity in groups 
treated with olanzapine, olanzapine plus cafeteria diet, and 
cafeteria diet alone. Regarding complex IV activity, we found 
no significant alteration among the groups within muscle tis-
sue. Nevertheless, in the liver, complex IV activity increased 
in olanzapine-treated groups compared to saline-treated ones. 
Data from literature demonstrate that the effects of leptin 
are mediated by the liver.39 Thus, our results suggest increased 
oxygen consumption, which consequently increases the basal 
metabolic level and the activities of complexes II and IV. 
Streck et al.40 showed that chronic administration of 
antipsychotics, including olanzapine, does not alter complex 
IV activity in rat brains. The same study showed reduced 
complex II activity in rat cerebellums with olanzapine treat-
ment. Oxidative stress was also assessed with the use of 
antipsychotics; lipid peroxidation is observed in different 
brain regions, leading to the formation of free radicals, which 
results in neuronal injury.32
Conclusion
Schizophrenia is a highly debilitating mental disease that 
features chronic cognitive deficits that significantly affect the 
lives of patients and their guardians. Our research indicates 
that adverse metabolic effects are still important challenges 
that should be overcome by psychopharmacology.
We believe that the discrepancies found in the metabolic 
profiles of these animals could be attributed to the dosage of 
olanzapine that was used, or because of the short duration 
of the experiment. Olanzapine is a drug that is used chroni-
cally and its side effects such as metabolic alterations and 
weight gain can be observed after a few weeks of use. In our 
study, the duration of the experiment was much shorter, so 
we could not observe the alterations expected.
Interestingly, during the course of this study, we observed 
leptin reduction in both groups which were on olanzapine 
and alterations of mitochondrial complex II and complex IV. 
These findings suggest a possible link between metabolic 
deficits and mitochondrial dysfunction following olanzapine 
treatment. Furthermore, the association between mental 
illness and cardiometabolic risks suggests that psychiatrists 
must play an important role in evaluating and monitoring such 
risks coupled with the use of antipsychotic drugs. 
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